GISSI-2 and the heparin controversy
- 4 August 1990
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 336 (8710), 297-298
- https://doi.org/10.1016/0140-6736(90)91818-u
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparinThe Lancet, 1990
- Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trialJournal of the American College of Cardiology, 1990
- Transient and symptomatic reocclusion early after thrombolysis for acute infarction: Incidence and significanceJournal of the American College of Cardiology, 1990
- Effect of Intravenous Streptokinase as Compared with That of Tissue Plasminogen Activator on Left Ventricular Function after First Myocardial InfarctionNew England Journal of Medicine, 1989
- Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.Circulation, 1988
- Effect of heparin and contrast medium on platelet function during routine cardiac catheterisationCardiovascular Research, 1987
- Intermittent Coronary Occlusion in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Pathophysiology of Myocardial ReperfusionAnnual Review of Medicine, 1985